Beam Therapeutics (BEAM) Net Margin (2019 - 2026)
Beam Therapeutics (BEAM) posted quarterly Net Margin of 297.18% for Q1 2026, up 115302.0% year-over-year from N/an in Q1 2025, and down 238.81% quarter-over-quarter from 214.09% in Q4 2025.
Powered by 
Analysis
Beam Therapeutics (BEAM) Net Margin (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has reported Net Margin for 8 consecutive years, with 297.18% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin rose 115302.0% year-over-year to 297.18%; the TTM figure through Mar 2026 stood at 39.66% (up 56811.0% YoY), while the FY2025 annual figure was 57.24%, up 53588.0% from the prior year.
- Net Margin eased to 297.18% in Q1 2026 per BEAM's latest filing, from 214.09% in the prior quarter.
- Across five years, Net Margin topped out at 214.09% in Q4 2025 and bottomed at 1450.2% in Q1 2025.
- Historically, Net Margin has averaged 614.62% across 5 years, with a median of 558.88% in 2023.
- Annual changes were most pronounced in 2022 — Net Margin surged 335851248 bps — and 2024, when it plunged 93310 bps.
- Beam Therapeutics' Net Margin stood at 191.39% in 2022, then jumped by 124 bps to 45.16% in 2023, then slumped by 765 bps to 300.51% in 2024, then surged by 171 bps to 214.09% in 2025, then plunged by 239 bps to 297.18% in 2026.
- Business Quant data shows BEAM's Net Margin at 297.18% in Q1 2026, 214.09% in Q4 2025, and 1162.38% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Beam Therapeutics | 3.10 Bn | 3.10 Bn | - | -25,036.33% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25,036.33% |
| Mar 31, 2026 | -297.18% |
| Dec 31, 2025 | 214.09% |
| Sep 30, 2025 | -1,162.38% |
| Jun 30, 2025 | -1,206.45% |
| Mar 31, 2025 | -1,450.20% |
| Dec 31, 2024 | -300.51% |
| Sep 30, 2024 | -677.47% |
| Jun 30, 2024 | -773.45% |
| Mar 31, 2024 | -1,331.57% |
| Dec 31, 2023 | 45.16% |
| Sep 30, 2023 | -558.88% |
| Jun 30, 2023 | -411.49% |
| Mar 31, 2023 | -398.46% |
| Dec 31, 2022 | -191.39% |
| Sep 30, 2022 | -693.56% |
| Jun 30, 2022 | -432.08% |
| Mar 31, 2022 | -820.85% |
| Dec 31, 2021 | -126.71% |
| Sep 30, 2021 | -3,685.19% |